(Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effective.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment